Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Euronext Paris  >  Adocia    ADOC   FR0011184241

ADOCIA (ADOC)
Mes dernières consult.
Most popular
  Report  
Delayed Quote. Delayed  - 04/26 05:35:44 pm
20.7 EUR   +26.99%
04/11ADOCIA SAS : quaterly sales release
03/31ADOCIA : Monthly statement on outstanding equity shares and voting r..
CO
03/14ADOCIA SAS : annual earnings release
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Business Summary
Logo Adocia
Operates as a clinical-stage biotechnology company

Adocia SA operates as a clinical-stage biotechnology company, which engages in the development of medicines from already approved therapeutic agents.

Its product pipeline includes BioChaperone PDGF, which is in Phase III clinical trials for the treatment of diabetic foot ulcer; BioChaperone insulin that is in Phase I/II clinical trials, as well as in pre-clinical staged for the treatment of diabetes; and Driveln, which is in preclinical stage for the treatment of oncology.

The company was founded by Gérard Soula, OLivier Soula, and Rémi Soula on December 16, 2005 and is headquartered in Lyon, France.


Sales per Businesses
20152016Delta
EUR (in Million)%EUR (in Million)%
License19.8953.8%10.7547.8% -45.95%
Research Contracts17.0546.2%11.7452.2% -31.14%
Sales per Regions
20152016Delta
EUR (in Million)%EUR (in Million)%
France36.94100%22.49100% -39.12%
Managers
NameAgeSinceTitle
Gérard Soula PhD, MBA702005Chairman, President & Chief Executive Officer
Valérie Danaguezian-2006Chief Financial Officer & Administrative Director
Olivier Soula PhD, MBA492005Director, Deputy General Manager, Director-R&D
Stanislav Glezer MD, MBA-2017Chief Medical Officer
Martin Gaudier, Phd--Scientific Director
Olivier Martinez PhD, MBA48-Director
Laurent Arthaud56-Director
Dominique Takizawa612011Independent Director
Ekaterina Smirnyagina, PhD512013Independent Director
Rémi Soula PhD, MBA-2005Director-Business Development
Equities
Vote QuantityFloatCompany-owned sharesTotal Float
Share A 1 6,861,763 5,305,718 77.3% 6,671 0.1% 77.3%
Shareholders
NameEquities%
Gérard Soula PhD, MBA 898,463 13.0%
BPIFrance Investissement SAS 738,639 10.7%
La Société Hospitalière d'Assurances Mutuelles SA 320,000 4.63%
Rémi Soula PhD, MBA 300,490 4.35%
Olivier Soula PhD, MBA 297,490 4.30%
ACG Management SAS 67,439 0.98%
CM-CIC Asset Management SA 50,080 0.72%
Oreo Finance SAS 40,561 0.59%
OP Asset Management Ltd. 37,113 0.54%
Uzes Gestion SA 20,000 0.29%
Markets and indexes
- PEA / SRD eligible : YES / YES
- Euronext Paris
- Compartiment C
- CAC All Shares / CAC All-Tradable, CAC Mid Small, CAC PME, CAC Small, EnterNext© PEA-PME 150, Next Biotech, PEA, PEA-PME
Stock Exchange Codes
- Bloomberg Code :  ADOC:FP
- Reuters Code :  ADOC.PA
- Datastream Code :  
Company contact information
Adocia
115 avenue Lacassagne
FR-69003 Lyon
France

Phone : +33 (0)4 72 610 610
Fax : +33 (0)4 72 36 39 67
Internet : http://www.adocia.com
Sector Bio Therapeutic Drugs
1st jan.Capitalization (M$)
ADOCIA13.59%141
GILEAD SCIENCES1.51%94 816
VERTEX PHARMACEUTICALS3.88%39 523
REGENERON PHARMACEUTICALS-17.01%33 601
GENMAB18.71%12 384
BEIGENE LTD (ADR)69.87%9 095
BLUEBIRD BIO INC-8.70%8 147
AVEXIS INC91.99%7 734
TONGHUA DONGBAO PHARMACEUTICAL CO., LTD.17.08%7 253
NEUROCRINE BIOSCIENCES, INC.1.08%7 049
EXELIXIS, INC.-31.48%6 052
BIOCON LTD21.08%5 857
SAREPTA THERAPEUTICS INC39.83%4 964
PEPTIDREAM INC11.58%4 909
AGIOS PHARMACEUTICALS INC47.59%4 818
BEIJING SL PHARMACEUTICAL CO LTD--.--%4 542
HUALAN BIOLOGICAL ENGINEERING INC--.--%4 264
LOXO ONCOLOGY INC57.46%3 890
ANHUI ANKE BIOTECHNOLOGY (GROUP) CO LTD--.--%3 105
TESARO INC-37.52%2 905
ARRAY BIOPHARMA INC8.05%2 867
Connections : Adocia
© 2018 People , Fundamentals and Ownership    © 2018 Cofisem